Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
64 hedge funds and large institutions have $14M invested in Nymox Pharmaceutical Corp in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 24 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 63 → 64 (+1)
29% less capital invested
Capital invested by funds: $19.9M → $14M (-$5.84M)
42% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 24
44% less call options, than puts
Call options by funds: $55K | Put options by funds: $99K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$297K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$238K |
| 3 |
State Street
Boston,
Massachusetts
|
+$216K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$201K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$55.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$147K |
| 2 |
Squarepoint
New York
|
-$128K |
| 3 |
Jane Street
New York
|
-$117K |
| 4 |
SG Americas Securities
New York
|
-$76K |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$72.8K |
NYMX Hedge Fund Activity: Q3 2020 in Review
64 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q3 2020, worth a combined $14M — down 29% from $19.9M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new NYMX positions and 6 closed out — a net gain of 1 holder — while 14 added to existing stakes and 24 trimmed.
The largest buyer was Worth Venture Partners, opening a new position worth an estimated $297K. The largest seller was Bank of America, cutting an estimated $147K.
- 64 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q3 2020, up from 63 in Q2 2020.
- Funds reported $14M of Nymox Pharmaceutical Corp stock for Q3 2020, down 29% quarter-over-quarter.
- 7 funds opened new Nymox Pharmaceutical Corp positions in Q3 2020 and 6 closed out, a net change of +1 holder.
- The largest Nymox Pharmaceutical Corp buyer in Q3 2020 was Worth Venture Partners, an estimated $297K added.
- The largest Nymox Pharmaceutical Corp seller in Q3 2020 was Bank of America, an estimated $147K sold.
Based on aggregated 13F filings for Q3 2020.